Mitochondrial dysfunction and Down's syndrome: Is there a role for coenzyme Q 10?

BioFactors

Volumn 37, Issue 5, 2011, Pages 386-392

  Tiano, Luca ^a   Busciglio, Jorge ^b  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; CoQ 10; Down's syndrome; Energy metabolism; Mitochondrial dysfunction; Oxidative stress; Progeroid syndromes

Indexed keywords

ALPHA TOCOPHEROL; PURINE; UBIDECARENONE;

CELL LEVEL; CENTRAL NERVOUS SYSTEM; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DAMAGE; DNA REPAIR; DOWN SYNDROME; DRUG MEGADOSE; ENERGY METABOLISM; HUMAN; LOW DRUG DOSE; MIGRAINE; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PARKINSONISM; PHENOTYPE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW;

ANIMALS; DNA REPAIR; DOWN SYNDROME; FREE RADICAL SCAVENGERS; HUMANS; MITOCHONDRIA; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UBIQUINONE;

ANIMALIA; LEPTOSPIRA;

EID: 80054875852     PISSN: 09516433     EISSN: 18728081     Source Type: Journal    
DOI: 10.1002/biof.184     Document Type: Review

References (87)

1. Zana, M., Janka, Z., and Kalman, J. (2007) Oxidative stress: a bridge between Down's syndrome and Alzheimer's disease. Neurobiol. Aging 28, 648-676.
2. Rachidi, M. and Lopes, C. (2007) Mental retardation in Down syndrome: from gene dosage imbalance to molecular and cellular mechanisms. Neurosci. Res. 59, 349-369.
3. Reeves, R. H. (2001) Down's syndrome. A complicated genetic insult. Lancet 358 Suppl, S23.
4. Antonarakis, S. E. (2001) Chromosome 21: from sequence to applications. Curr. Opin. Genet. Dev. 11, 241-246.
5. Antonarakis, S. E., Lyle, R., Dermitzakis, E. T., Reymond, A., and Deutsch, S. (2004) Chromosome 21 and down syndrome: from genomics to pathophysiology. Nat. Rev. Genet. 5, 725-738.
6. Pritchard, M. A. and Kola, I. (1999) The "gene dosage effect" hypothesis versus the "amplified developmental instability" hypothesis in Down syndrome. J. Neural Transm. Suppl 57, 293-303.
7. Hall, B. (1965) Delayed ontogenesis in human trisomy syndromes. Hereditas 52, 334-344.
8. Moldrich, R. X., Dauphinot, L., Laffaire, J., Rossier, J., and Potier, M. C. (2007) Down syndrome gene dosage imbalance on cerebellum development. Prog. Neurobiol. 82, 87-94.
9. Busciglio, J. and Yankner, B. A. (1995) Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 378, 776-779.
10. Busciglio, J., Pelsman, A., Wong, C., Pigino, G., Yuan, M., Mori, H., and Yankner, B. A. (2002) Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron 33, 677-688.
11. Lott, I. T., Head, E., Doran, E., and Busciglio, J. (2006) Beta-amyloid, oxidative stress and down syndrome. Curr. Alzheimer Res. 3, 521-528.
12. Capone, G. T. (2001) Down syndrome: advances in molecular biology and the neurosciences. J. Dev. Behav. Pediatr. 22, 40-59.
13. Pallardo, F. V., Degan, P., d'Ischia, M., Kelly, F. J., Zatterale, A., Calzone, R., Castello, G., Fernandez-Delgado, R., Dunster, C., Lloret, A., Manini, P., Pisanti, M. A., Vuttariello, E., and Pagano, G. (2006) Multiple evidence for an early age pro-oxidant state in Down syndrome patients. Biogerontology 7, 211-220.
14. Zana, M., Szecsenyi, A., Czibula, A., Bjelik, A., Juhasz, A., Rimanoczy, A., Szabo, K., Vetro, A., Szucs, P., Varkonyi, A., Pakaski, M., Boda, K., Rasko, I., Janka, Z., and Kalman, J. (2006) Age-dependent oxidative stress-induced DNA damage in Down's lymphocytes. Biochem. Biophys. Res. Commun. 345, 726-733.
15. Tiano, L., Padella, L., Santoro, L., Carnevali, P., Principi, F., Bruge, F., Gabrielli, O., and Littarru, G. P. (2011) Prolonged coenzyme Q(10)treatment in Down syndrome patients, effect on DNA oxidation. Neurobiol. Aging, DOI: 10.1016/j.neurobiolaging.2011.03.025.
16. Kedziora, J. and Bartosz, G. (1988) Down's syndrome: a pathology involving the lack of balance of reactive oxygen species. Free Radic. Biol. Med. 4, 317-330.
17. Groner, Y., Elroy-Stein, O., Avraham, K. B., Schickler, M., Knobler, H., Minc-Golomb, D., Bar-Peled, O., Yarom, R., and Rotshenker, S. (1994) Cell damage by excess CuZnSOD and Down's syndrome. Biomed. Pharmacother. 48, 231-240.
18. Capone, G., Kim, P., Jovanovich, S., Payne, L., Freund, L., Welch, K., Miller, E., and Trush, M. (2002) Evidence for increased mitochondrial superoxide production in Down syndrome. Life Sci. 70, 2885-2895.
19. Lott, I. T., Doran, E., Walsh, D. M., and Hill, M. A. (2006) Telemedicine, dementia and Down syndrome: implications for Alzheimer disease. Alzheimers. Dement. 2, 179-184.
20. Jomova, K. and Valko, M. (2011) Advances in metal-induced oxidative stress and human disease. Toxicology 283, 65-87.
21. Sastre, J., Pallardo, F. V., and Vina, J. (2003) The role of mitochondrial oxidative stress in aging. Free Radic. Biol. Med. 35, 1-8.
22. Costa, R. A., Romagna, C. D., Pereira, J. L., and Souza-Pinto, N. C. (2011) The role of mitochondrial DNA damage in the citotoxicity of reactive oxygen species. J. Bioenerg. Biomembr. 43, 25-29.
23. Stuart, J. A. and Brown, M. F. (2006) Mitochondrial DNA maintenance and bioenergetics. Biochim. Biophys. Acta 1757, 79-89.
24. Busciglio, J. The role of oxidative stress and mitochondrial dysfunction in Down's syndrome. Sixth Conference of the International Coenzyme Q10 Association, Brussels May 27-30, 2010.
25. Garcia, O., Torres, M., Helguera, P., Coskun, P., and Busciglio, J. (2010) A role for thrombospondin-1 deficits in astrocyte-mediated spine and synaptic pathology in Down's syndrome. PLoS One 5, e14200.
26. Vila, M., Ramonet, D., and Perier, C. (2008) Mitochondrial alterations in Parkinson's disease: new clues. J. Neurochem. 107, 317-328.
27. Wang, X., Su, B., Lee, H. G., Li, X., Perry, G., Smith, M. A., and Zhu, X. (2009) Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J. Neurosci. 29, 9090-9103.
28. Arbuzova, S., Hutchin, T., and Cuckle, H. (2002) Mitochondrial dysfunction and Down's syndrome. Bioessays 24, 681-684.
29. Coskun, P. E., Wyrembak, J., Derbereva, O., Melkonian, G., Doran, E., Lott, I. T., Head, E., Cotman, C. W., and Wallace, D. C. (2010) Systemic mitochondrial dysfunction and the etiology of Alzheimer's disease and down syndrome dementia. J. Alzheimers. Dis. 20 Suppl 2, S293-S310.
30. Park, J., Oh, Y., and Chung, K. C. (2009) Two key genes closely implicated with the neuropathological characteristics in Down syndrome: DYRK1A and RCAN1. BMB. Rep. 42, 6-15.
31. Park, J., Song, W. J., and Chung, K. C. (2009) Function and regulation of Dyrk1A: towards understanding Down syndrome. Cell Mol. Life Sci. 66, 3235-3240.
32. Wegiel, J., Gong, C. X., and Hwang, Y. W. (2011) The role of DYRK1A in neurodegenerative diseases. FEBS J. 278, 236-245.
33. Lee, J. E., Jang, H., Cho, E. J., and Youn, H. D. (2009) Down syndrome critical region 1 enhances the proteolytic cleavage of calcineurin. Exp. Mol. Med. 41, 471-477.
34. Cereghetti, G. M., Costa, V., and Scorrano, L. (2010) Inhibition of Drp1-dependent mitochondrial fragmentation and apoptosis by a polypeptide antagonist of calcineurin. Cell Death. Differ. 17, 1785-1794.
35. Tan, A. R., Cai, A. Y., Deheshi, S., and Rintoul, G. L. (2011) Elevated intracellular calcium causes distinct mitochondrial remodelling and calcineurin-dependent fission in astrocytes. Cell Calcium 49, 108-114.
36. Littarru, G. P. and Tiano, L. (2010) Clinical aspects of coenzyme Q10: an update. Nutrition 26, 250-254.
37. Estornell, E., Fato, R., Castelluccio, C., Cavazzoni, M., Parenti, C. G., and Lenaz, G. (1992) Saturation kinetics of coenzyme Q in NADH and succinate oxidation in beef heart mitochondria. FEBS Lett. 311, 107-109.
38. Naini, A., Lewis, V. J., Hirano, M., and DiMauro, S. (2003) Primary coenzyme Q10 deficiency and the brain. Biofactors 18, 145-152.
39. Mortensen, S. A. (2003) Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of "Q-symbio"-a multinational trial. Biofactors 18, 79-89.
40. Yang, X., Yang, Y., Li, G., Wang, J., and Yang, E. S. (2008) Coenzyme Q10 attenuates beta-amyloid pathology in the aged transgenic mice with Alzheimer presenilin 1 mutation. J. Mol. Neurosci. 34, 165-171.
41. Beal, M. F. (2009) Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease. Parkinsonism Relat. Disord. 15 Suppl 3, S189-S194.
42. Gille, G., Hung, S. T., Reichmann, H., and Rausch, W. D. (2004) Oxidative stress to dopaminergic neurons as models of Parkinson's disease. Ann. N. Y. Acad. Sci. 1018, 533-540.
43. Shults, C. W., Oakes, D., Kieburtz, K., Beal, M. F., Haas, R., Plumb, S., Juncos, J. L., Nutt, J., Shoulson, I., Carter, J., Kompoliti, K., Perlmutter, J. S., Reich, S., Stern, M., Watts, R. L., Kurlan, R., Molho, E., Harrison, M., and Lew, M. (2002) Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol. 59, 1541-1550.
44. Cooper, J. M. and Schapira, A. H. (2007) Friedreich's ataxia: coenzyme Q10 and vitamin E therapy. Mitochondrion. 7 Suppl, S127-S135.
45. Cooper, J. M., Korlipara, L. V., Hart, P. E., Bradley, J. L., and Schapira, A. H. (2008) Coenzyme Q10 and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur. J. Neurol. 15, 1371-1379.
46. Stamelou, M., Reuss, A., Pilatus, U., Magerkurth, J., Niklowitz, P., Eggert, K. M., Krisp, A., Menke, T., Schade-Brittinger, C., Oertel, W. H., and Hoglinger, G. U. (2008) Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord. 23, 942-949.
47. Sandor, P. S., Di Clemente, L., Coppola, G., Saenger, U., Fumal, A., Magis, D., Seidel, L., Agosti, R. M., and Schoenen, J. (2005) Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 64, 713-715.
48. Hershey, A. D., Powers, S. W., Vockell, A. L., Lecates, S. L., Ellinor, P. L., Segers, A., Burdine, D., Manning, P., and Kabbouche, M. A. (2007) Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. Headache 47, 73-80.
49. Tiano, L., Padella, L., Carnevali, P., Gabrielli, O., Bruge, F., Principi, F., and Littarru, G. P. (2008) Coenzyme Q10 and oxidative imbalance in Down syndrome: biochemical and clinical aspects. Biofactors 32, 161-167.
50. Miles, M. V., Patterson, B. J., Chalfonte-Evans, M. L., Horn, P. S., Hickey, F. J., Schapiro, M. B., Steele, P. E., Tang, P. H., and Hotze, S. L. (2007) Coenzyme Q10 (ubiquinol-10) supplementation improves oxidative imbalance in children with trisomy 21. Pediatr. Neurol. 37, 398-403.
51. Tiano, L., Littarru, G. P., Principi, F., Orlandi, M., Santoro, L., Carnevali, P., and Gabrielli, O. (2005) Assessment of DNA damage in Down Syndrome patients by means of a new, optimised single cell gel electrophoresis technique. Biofactors 25, 187-195.
52. Tomasetti, M., Littarru, G. P., Stocker, R., and Alleva, R. (1999) Coenzyme Q10 enrichment decreases oxidative DNA damage in human lymphocytes. Free Radic. Biol. Med. 27, 1027-1032.
53. Tiano, L., Carnevali, P., Padella, L., Santoro, L., Principi, F., Bruge, F., Carle, F., Gesuita, R., Gabrielli, O., and Littarru, G. P. (2009) Effect of Coenzyme Q(10)in mitigating oxidative DNA damage in Down syndrome patients, a double blind randomized controlled trial. Neurobiol. Aging, DOI: 10.1016/j.neurobiolaging.2009.11.016.
54. Tomasetti, M., Alleva, R., Borghi, B., and Collins, A. R. (2001) In vivo supplementation with coenzyme Q10 enhances the recovery of human lymphocytes from oxidative DNA damage. FASEB J. 15, 1425-1427.
55. Vina, J., Borras, C., Gambini, J., Sastre, J., and Pallardo, F. V. (2005) Why females live longer than males: control of longevity by sex hormones. Sci. Aging Knowledge Environ. 2005, e17.
56. Raji, N. S. and Rao, K. S. (1998) Trisomy 21 and accelerated aging: DNA-repair parameters in peripheral lymphocytes of Down's syndrome patients. Mech. Ageing Dev. 100, 85-101.
57. Loft, S., Hogh, D. P., Mikkelsen, L., Risom, L., Forchhammer, L., and Moller, P. (2008) Biomarkers of oxidative damage to DNA and repair. Biochem. Soc. Trans. 36, 1071-1076.
58. Papucci, L., Schiavone, N., Witort, E., Donnini, M., Lapucci, A., Tempestini, A., Formigli, L., Zecchi-Orlandini, S., Orlandini, G., Carella, G., Brancato, R., and Capaccioli, S. (2003) Coenzyme q10 prevents apoptosis by inhibiting mitochondrial depolarization independently of its free radical scavenging property. J. Biol. Chem. 278, 28220-28228.
59. Chaturvedi, R. K. and Beal, M. F. (2008) Mitochondrial approaches for neuroprotection. Ann. N. Y. Acad. Sci. 1147, 395-412.
60. Mancuso, M., Orsucci, D., Volpi, L., Calsolaro, V., and Siciliano, G. (2010) Coenzyme Q10 in neuromuscular and neurodegenerative disorders. Curr. Drug Targets. 11, 111-121.
61. Bogeski, I., Gulaboski, R., Kappl, R., Mirceski, V., Stefova, M., Petreska, J., and Hoth, M. (2011) Calcium binding and transport by coenzyme q. J. Am. Chem. Soc. 133, 9293-9303.
62. Contestabile, A., Benfenati, F., and Gasparini, L. (2010) Communication breaks-Down: from neurodevelopment defects to cognitive disabilities in Down syndrome. Prog. Neurobiol. 91, 1-22.
63. Du, H. and Yan, S. S. (2010) Mitochondrial medicine for neurodegenerative diseases. Int. J. Biochem. Cell Biol. 42, 560-572.
64. Matthews, R. T., Yang, L., Browne, S., Baik, M., and Beal, M. F. (1998) Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc. Natl. Acad. Sci. U. S. A 95, 8892-8897.
65. Beal, M. F. (1998) Mitochondrial dysfunction in neurodegenerative diseases. Biochim. Biophys. Acta 1366, 211-223.
66. Ferrante, K. L., Shefner, J., Zhang, H., Betensky, R., O'Brien, M., Yu, H., Fantasia, M., Taft, J., Beal, M. F., Traynor, B., Newhall, K., Donofrio, P., Caress, J., Ashburn, C., Freiberg, B., O'Neill, C., Paladenech, C., Walker, T., Pestronk, A., Abrams, B., Florence, J., Renna, R., Schierbecker, J., Malkus, B., and Cudkowicz, M. (2005) Tolerance of high-dose (3, 000 mg/day) coenzyme Q10 in ALS. Neurology 65, 1834-1836.
67. Shults, C. W., Haas, R., Oakes, D., Kieburtz, K., Plumb, S., Shoulson, I., Beal, M. F., Juncos, J., and Nutt, J. (2004) Measuring the effects of therapy in Parkinson disease. JAMA 291, 2430-2431.
68. Senin, U., Parnetti, L., Barbagallo-Sangiorgi, G., Bartorelli, L., Bocola, V., Capurso, A., Cuzzupoli, M., Denaro, M., Marigliano, V., Tammaro, A. E., and Fioravanti, M. (1992) Idebenone in senile dementia of Alzheimer type: a multicentre study. Arch. Gerontol. Geriatr. 15, 249-260.
69. Gutzmann, H. and Hadler, D. (1998) Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study. J. Neural Transm. Suppl 54, 301-310.
70. Swerdlow, R. H., Burns, J. M., and Khan, S. M. (2010) The Alzheimer's disease mitochondrial cascade hypothesis. J. Alzheimers. Dis. 20 Suppl 2, S265-S279.
71. Park, I. H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M. W., Cowan, C., Hochedlinger, K., and Daley, G. Q. (2008) Disease-specific induced pluripotent stem cells. Cell 134, 877-886.
72. Muchova, J., Sustrova, M., Garaiova, I., Liptakova, A., Blazicek, P., Kvasnicka, P., Pueschel, S., and Durackova, Z. (2001) Influence of age on activities of antioxidant enzymes and lipid peroxidation products in erythrocytes and neutrophils of Down syndrome patients. Free Radic. Biol. Med. 31, 499-508.
73. Pastor, M. C., Sierra, C., Dolade, M., Navarro, E., Brandi, N., Cabre, E., Mira, A., and Seres, A. (1998) Antioxidant enzymes and fatty acid status in erythrocytes of Down's syndrome patients. Clin. Chem. 44, 924-929.
74. Garcez, M. E., Peres, W., and Salvador, M. (2005) Oxidative stress and hematologic and biochemical parameters in individuals with Down syndrome. Mayo Clin. Proc. 80, 1607-1611.
75. Zitnanova, I., Korytar, P., Aruoma, O. I., Sustrova, M., Garaiova, I., Muchova, J., Kalnovicova, T., Pueschel, S., and Durackova, Z. (2004) Uric acid and allantoin levels in Down syndrome: antioxidant and oxidative stress mechanisms?. Clin. Chim. Acta 341, 139-146.
76. Campos, C., Guzman, R., Lopez-Fernandez, E., and Casado, A. (2011) Evaluation of urinary biomarkers of oxidative/nitrosative stress in adolescents and adults with Down syndrome. Biochim. Biophys. Acta 1812, 760-768.
77. Jovanovic, S. V., Clements, D., and MacLeod, K. (1998) Biomarkers of oxidative stress are significantly elevated in Down syndrome. Free Radic. Biol. Med. 25, 1044-1048.
78. Pratico, D., Iuliano, L., Amerio, G., Tang, L. X., Rokach, J., Sabatino, G., and Violi, F. (2000) Down's syndrome is associated with increased 8, 12-iso-iPF2alpha-VI levels: evidence for enhanced lipid peroxidation in vivo. Ann. Neurol. 48, 795-798.
79. Brooksbank, B. W. and Balazs, R. (1984) Superoxide dismutase, glutathione peroxidase and lipoperoxidation in Down's syndrome fetal brain. Brain Res. 318, 37-44.
80. Balcz, B., Kirchner, L., Cairns, N., Fountoulakis, M., and Lubec, G. (2001) Increased brain protein levels of carbonyl reductase and alcohol dehydrogenase in Down syndrome and Alzheimer's disease. J. Neural Transm. Suppl. 193-201.
81. Bersu, E. T., Ahmad, F. J., Schwei, M. J., and Baas, P. W. (1998) Cytoplasmic abnormalities in cultured cerebellar neurons from the trisomy 16 mouse. Brain Res. Dev. Brain Res. 109, 115-120.
82. Conti, A., Fabbrini, F., D'Agostino, P., Negri, R., Greco, D., Genesio, R., D'Armiento, M., Olla, C., Paladini, D., Zannini, M., and Nitsch, L. (2007) Altered expression of mitochondrial and extracellular matrix genes in the heart of human fetuses with chromosome 21 trisomy. BMC Genom. 8, 268.
83. Druzhyna, N., Nair, R. G., LeDoux, S. P., and Wilson, G. L. (1998) Defective repair of oxidative damage in mitochondrial DNA in Down's syndrome. Mutat. Res. 409, 81-89.
84. Prince, J., Jia, S., Bave, U., Anneren, G., and Oreland, L. (1994) Mitochondrial enzyme deficiencies in Down's syndrome. J. Neural Transm. Park Dis. Dement. Sect. 8, 171-181.
85. Schuchmann, S. and Heinemann, U. (2000) Increased mitochondrial superoxide generation in neurons from trisomy 16 mice: a model of Down's syndrome. Free Radic. Biol. Med. 28, 235-250.
86. Bambrick, L. L. and Fiskum, G. (2008) Mitochondrial dysfunction in mouse trisomy 16 brain. Brain Res. 1188, 9-16.
87. Roat, E., Prada, N., Ferraresi, R., Giovenzana, C., Nasi, M., Troiano, L., Pinti, M., Nemes, E., Lugli, E., Biagioni, O., Mariotti, M., Ciacci, L., Consolo, U., Balli, F., and Cossarizza, A. (2007) Mitochondrial alterations and tendency to apoptosis in peripheral blood cells from children with Down syndrome. FEBS Lett. 581, 521-525.